The investigators will test the central hypothesis that DFO treatment after SAH may improve cerebrovascular regulation, mitigate ischemic neural injury, and serve as an effective neuroprotectant against delayed ischemic injury after SAH.
Trial Stopped: Principle Investigator is moving to another institution and plans to restart this proctocol in the new location.
- Placebo Biological
Intervention Desc: normal saline IV for 4 hours for 5 consecutive days ARM 1: Kind: Experimental Label: placebo Description: normal saline IV for 4 hours for 5 consecutive days
- Desferrioxamine (DFO) Drug
Other Names: deferoxamine, desferal, DFO, deferoxamine mesylate Intervention Desc: DFO (20mg/kg/hr) in normal saline for 4 hours for 5 consecutive days ARM 1: Kind: Experimental Label: Desferrioxamine (DFO) Description: DFO (20mg/kg/hr) in normal saline IV for 4 hours for 5 consecutive days
- Allocation: Randomized
- Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
- Purpose: Treatment
- Endpoint: Efficacy Study
- Intervention: Parallel Assignment
|Type||Measure||Time Frame||Safety Issue|
|Primary||delayed cerebral ischemia (DCI)||6 weeks post hemorrhage||No|
|Secondary||Clinical outcome at discharge||patient's discharge date, which averages 3-4 weeks post hemorrhage||No|